These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 4069764)

  • 1. Dialysis osteomalacia: a possible role for zirconium as well as aluminium.
    Ham KN; Brown DJ; Dawborn JK; Johnson CI; Nelson S; Xipell JM
    Pathology; 1985 Jul; 17(3):458-63. PubMed ID: 4069764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The localization of aluminium and other elements in bone tissue of a case of renal osteodystrophy with an associated dialysis encephalopathy syndrome.
    McClure J; Smith PS
    J Pathol; 1984 Apr; 142(4):293-9. PubMed ID: 6716213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of dialysis osteomalacia with desferrioxamine.
    Brown DJ; Dawborn JK; Ham KN; Xipell JM
    Lancet; 1982 Aug; 2(8294):343-5. PubMed ID: 6124756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of fracturing renal osteodystrophy by desferrioxamine.
    Ackrill P; Day JP; Garstang FM; Hodge KC; Metcalfe PJ; Benzo Z; Hill K; Ralston AJ; Ball J; Denton J
    Proc Eur Dial Transplant Assoc; 1983; 19():203-7. PubMed ID: 6878234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoride and strontium accumulation in bone does not correlate with osteoid tissue in dialysis patients.
    Cohen-Solal ME; Augry F; Mauras Y; Morieux C; Allain P; de Vernejoul MC
    Nephrol Dial Transplant; 2002 Mar; 17(3):449-54. PubMed ID: 11865091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interaction of parathyroid hormone and aluminum in renal osteodystrophy.
    Slatopolsky E
    Kidney Int; 1987 Mar; 31(3):842-54. PubMed ID: 3573543
    [No Abstract]   [Full Text] [Related]  

  • 8. Aluminium-related osteodystrophy and desferrioxamine treatment: role of phosphorus.
    Jorgetti V; Soeiro NM; Mendes V; Pereira RC; Crivellari ME; Coutris G; Borelli A; Leite MO; Nussenzweig I; Marcondes M
    Nephrol Dial Transplant; 1994; 9(6):668-74. PubMed ID: 7970094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of intravenous and intraperitoneal desferrioxamine in aluminium osteomalacia.
    O'Brien AA; McParland C; Keogh JA
    Nephrol Dial Transplant; 1987; 2(2):117-9. PubMed ID: 3112649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteomalacic dialysis osteodystrophy: a trial of phosphate-enriched dialysis fluid.
    Feest TG; Ward MK; Ellis HA; Aljama P; Kerr DN
    Br Med J; 1978 Jan; 1(6104):18-20. PubMed ID: 620130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aluminum-related osteomalacia: clinical and histological improvement following treatment with desferrioxamine (DFO).
    Rapoport J; Chaimovitz C; Abulfil A; Mostovlavsky M; Gazit D; Bab I
    Isr J Med Sci; 1987 Dec; 23(12):1242-6. PubMed ID: 3440748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodialysis bone disease: correlation between clinical, histologic, and other findings.
    Alvarez-Ude F; Feest TG; Ward MK; Pierides AM; Ellis HA; Peart M; Simpson W; Weightman D; Kerr DN
    Kidney Int; 1978 Jul; 14(1):68-73. PubMed ID: 682426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoride and dialysis osteodystrophy: results of a double-blind study.
    Oreopoulos DG; Taves DR; Rabinovich S; Meema HE; Murray T; Fenton SS; deVeber GA
    Trans Am Soc Artif Intern Organs; 1974; 20A():203-8. PubMed ID: 4615422
    [No Abstract]   [Full Text] [Related]  

  • 14. [Desferrioxamine treatment of osteomalacia caused by aluminum poisoning].
    Charhon SA; Chavassieux P; Chapuy MC; Accominotti M; Traeger J; Meunier PJ
    Presse Med; 1986 Jan; 15(2):55-9. PubMed ID: 2935857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aluminium-induced bone disease in uremic rats: effect of deferoxamine.
    Jablonski G; Klem KH; Danielsen CC; Mosekilde L; Gordeladze JO
    Biosci Rep; 1996 Feb; 16(1):49-63. PubMed ID: 8861540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology and treatment of uremic bone disease.
    Coburn J; Kanis J; Popovtzer M; Ritz E; Slatopolsky E; Fleisch H
    Calcif Tissue Int; 1983 Sep; 35(6):712-4. PubMed ID: 6652544
    [No Abstract]   [Full Text] [Related]  

  • 17. Familial vitamin D deficient osteomalacia and renal osteodystrophy: shaping up the debate.
    Jabur WL
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):128-30. PubMed ID: 20061707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferoxamine-induced bone changes in haemodialysis patients: a histomorphometric study.
    Charhon SA; Chavassieux P; Boivin G; Parisien M; Chapuy MC; Traeger J; Meunier PJ
    Clin Sci (Lond); 1987 Aug; 73(2):227-34. PubMed ID: 3652627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation and localisation of aluminum in human cancellous bone in renal osteodystrophy.
    Boyce BF; Eider HY; Fell SG; Nicholson WA; Smith GD; Dempster DW; Gray CC; Boyle IT
    Scan Electron Microsc; 1981; (Pt 3):329-37. PubMed ID: 7330581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathogenesis of osteopathy in chronic renal insufficiency].
    Vel'tishchev IuE
    Pediatriia; 1974 Feb; (2):66-70. PubMed ID: 4619427
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.